Status:
COMPLETED
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Thrombosis
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
To estimate the pharmacokinetics of apixaban when administered as three different modified release formulation tablets relative to that when apixaban is administered as an immediate release tablet
Eligibility Criteria
Inclusion
- Healthy male or female patients
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2
Exclusion
- Any condition possibly affecting drug absorption
- History or evidence of abnormal bleeding or clotting disorder
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00914641
Start Date
June 1 2009
End Date
August 1 2009
Last Update
August 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511